Find out more about the portfolio

Schroder UK Public Private Trust plc

Overview of 10 largest investments

As at June 2022

Schroder UK Public Private Trust Plc invests in publicly listed and private companies which showcase the best in British innovation.

Oxford Nanopore


Technology company at the forefront of next generation DNA sequencing instrumentation

Oxford Nanopore Technologies is developing and commercialising a new generation of nanopore-based electronic systems for analysis of single molecules, including DNA, RNA and proteins. The handheld MinION™ device, the high-throughput/high sample number PromethION™ and the GridION™ system are designed to provide novel qualities in molecular sensing such as real-time data streaming, improved simplicity, efficiency and scalability of workflows and direct analysis of the molecule of interest. The devices may be used in scientific research, personalised medicine, crop science, security and defence and environmental applications and a number of applications, methods and tools have been published by MinION users.

Visit website >

Atom bank


Leading UK app-only challenger bank

Atom Bank is the UK’s first bank built exclusively for mobile. It is redefining what a bank should be, making things easier, more transparent and better value in a world of finance. Atom currently offers savings accounts, mortgages and business loans.

Visit website >

Benevolent AI


Technology company at the leading edge of developing and applying artificial intelligence for drug discovery and development

BenevolentAI creates and applies artificial intelligence (AI) and machine learning to transform the way medicines are discovered and developed. Benevolent integrates its technology into every step of the drug discovery process from hypothesis generation to late-stage clinical development. The Benevolent Platform® is used by scientists and technologists to find new ways to treat disease, improve the efficacy and lower the development time and costs of new treatments.

Visit website >



Pioneering clinical-stage T cell receptor biotechnology company working to develop and commercialize a new generation of transformative medicines.

Immunocore is a pioneering T cell receptor biotechnology company, working to develop and commercialise a new generation of transformative medicines to address unmet needs. The Company’s most advanced programmes are in oncology and it has a rich pipeline of programmes in infectious and autoimmune diseases. Its lead programme, Tebentafusp (IMCgp100), has entered pivotal clinical studies as a treatment for patients with metastatic uveal melanoma.

Visit website >

Reaction Engines


Developer of innovative high performance engine technologies to enable space and hypersonic travel

Reaction Engines is developing its innovative SABRE engine to enable space and hypersonic travel more efficieint and more accesible. Multiple applications are being spun off from this core vision creating a step change in performance and efficiency in an array of commercial industries.

Visit website >

IDEX Biometrics


Leading provider of fingerprint identification technologies.

IDEX Biometrics ASA is a leading provider of fingerprint identification technologies offering simple, secure and personal touch-free authentication. The technology enables people to make payments, prove their identity, gain access to information, unlock devices or gain admittance to buildings.

Visit website >

AMO Pharma


Developer of drugs to treat rare or orphan diseases.

AMO Pharma is a biopharmaceutical company working to identify and advance promising therapies for the treatment of serious and debilitating diseases in patient populations with significant areas of unmet need, including rare, debilitating childhood onset neurogenetic disorders with limited or no treatment options. As well as developing AMO-02 for congenital myotonic dystrophy, the company is progressing AMO-01 as a clinical stage treatment for Phelan McDermid Syndrome and AMO-04 as a clinic ready potential medicine for Rett Syndrome and related disorders.

Visit website >



Leading EU private growth equity fundraising and investment platform.

Seedrs was the first regulated investment crowdfunding platform in the world, and in 2019 it was the most active investor in UK private companies. It allows all types of investors to invest as little or as much as they like in businesses they believe in and share in their success, and it allows ambitious businesses in all sectors to raise capital and build community through an efficient, online process.

Visit website >

HP Environmental Technologies Fund


Portfolio of venture and growth-stage industrial companies.

HP Environmental Technologies Fund LP is the investment vehicle that acquired Ombu Group Limited, a specialist investor in early and growth stage environmental technologies.

Visit website >



Leading disruptive global neobank.

Revolut is building the world's first global financial superapp to help people get more from their money. In 2015, Revolut launched in the UK offering money transfer and exchange. Today, more than 16 million customers around the world use dozens of Revolut's innovative products to make more than 150 million transactions a month. Across personal and business accounts, Revolut helps customers improve their financial health, give them more control and connect people seamlessly across the world.

Visit website >

What are the risks?

Long-term outcomes are more binary – extremely attractive rewards for success but some businesses will inevitably fail to fulfil their potential and this may expose investors to the risk of capital losses

As it can take years for young businesses to fulfil their potential, this investment requires patience

The price of shares in the trust is determined by market supply and demand, and this may be different to the net asset value of the trust. This means the price may be volatile in response to changes in demand

The trust may invest in overseas securities and be exposed to currencies other than pound sterling – as a result, exchange rate movements may cause the value of the trust, individual investments, and any income paid to decrease or increase

The trust may invest in unquoted securities, which may be less liquid and more difficult to value, because they are generally not publicly traded – the lack of an open market may also make it more difficult to establish fair value

Young businesses have a different risk profile to mature blue-chip companies – risks are much more stock-specific, which implies a lower correlation with equity markets and the wider economy

The Company may borrow money to invest in further investments, this is known as gearing. Gearing will increase returns if the value of the investments purchased increase in value by more than the cost of borrowing, or reduce returns if they fail to do so.

Follow us

Please remember that the value of investments and the income from them may go down as well as up and investors may not get back the amounts originally invested.

This marketing material is for professional clients or advisers only. This site is not suitable for retail clients.

Issued by Schroder Unit Trusts Limited, 1 London Wall Place, London EC2Y 5AU. Registered Number 4191730 England.

For illustrative purposes only and does not constitute a recommendation to invest in the above-mentioned security / sector / country.

Schroder Unit Trusts Limited is an authorised corporate director, authorised unit trust manager and an ISA plan manager, and is authorised and regulated by the Financial Conduct Authority.

On 17 September 2018 our remaining dual priced funds converted to single pricing and a list of the funds affected can be found in our Changes to Funds. To view historic dual prices from the launch date to 14 September 2018 click on Historic prices.